By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Catalent and Novo Holdings

Unlocking Greater Value, Together

Transaction Overview

Catalent has entered into an agreement to be acquired by Novo Holdings, a global investment firm focused on life sciences. Following the close of the transaction, Catalent will benefit from Novo Holdings’ significant resources, allowing for accelerated investment in the Company and enhancement of current key offerings.

A Global Life Sciences and Healthcare Investment Firm

Novo Holdings is a global life sciences and healthcare investment firm. In addition to its life sciences investments across subsectors, it has a diversified portfolio of equities, credit, real estate and infrastructure assets.

Our Commitment

To continue to build and leverage an ecosystem that enables innovation to deliver better patient outcomes.

Quality Pharma Services

As a major pharma services company, Catalent enables its global pharma, biotech, and consumer health partners to optimize their own operations – starting with product development through to product launch and full life-cycle supply.

A Global Leading CDMO
Catalent
+
Novo Holdings

Novo Holdings to acquire Catalent

As announced on February 5, 2024

On May 29, 2024, Catalent stockholders voted to approve the pending transaction

The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions and receipt of required regulatory approvals

At that time, Catalent will become a private company continuing to focus on its mission of enabling the development and supply of better treatments for patients worldwide

In a separate transaction that will occur post-close, Novo Holdings intends to sell three of Catalent’s 50+ global sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium to Novo Nordisk

Catalent’s 50+ global sites

Novo Nordisk
Post-close, Novo Holdings intends to sell three of Catalent’s 50+ sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium and related assets to Novo Nordisk.
Novo Nordisk operates separately from Novo Holdings.
“Catalent will remain a leading global service provider to the biotech and pharmaceutical industries, following the completion of the transaction with Novo Holdings. Under private ownership, we will benefit from access to additional capital and resources to provide enhanced service for the benefit of customers and patients. Catalent is a Patient First organization with a mission to develop, manufacture and supply products that help people live better and healthier lives – and this will remain our top priority.”
Photo of Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc.
Alessandro Maselli
President and Chief Executive Officer of Catalent, Inc.
“We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the Company’s full potential.”
Photo of Kasim Kutay, CEO of Novo Holdings
Kasim Kutay
CEO of Novo Holdings

FAQs on Our Transaction with Novo Holdings

Transaction Resources

July 15, 2024
Endpoints Article: CDMO’s Critical Role in a Rapidly Evolving Biopharma Landscape
Read Article
July 15, 2024
Endpoints Webinar with Catalent CEO Alessandro Maselli
Watch Video
May 29, 2024
Special Meeting Results Press Release
Download PDF
February 5, 2024
Transaction Announcement Press Release
Download PDF
February 5, 2024
Novo Nordisk Fill-finish Site Transaction Announcement Press Release
Download PDF
Transaction Factsheet
Download PDF

Forward-Looking Statements

This website and any related oral statements, may include “forward-looking statements” within the meaning of, and subject to the safe harbor created by, the federal securities laws, including statements related to the Merger, including financial estimates and statements as to the expected timing, completion and effects of the Merger. These forward-looking statements are based on Catalent’s current expectations, estimates and projections regarding, among other things, the expected date of the closing and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by Catalent, all of which are subject to change. Forward-looking statements often contain words such as “expect,” “anticipate,” “intend,” “aims,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “considered,” “potential,” “estimate,” “continue,” “likely,” “expect,” “target,” “project,” or similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. By their nature, forward-looking statements address matters that involve risks and uncertainties because they relate to events and depend upon future circumstances that may or may not occur, such as the consummation of the Merger and the anticipated benefits thereof. These and other forward-looking statements, as well as any related oral statements, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the completion of the Merger on anticipated terms and timing, including obtaining antitrust and other regulatory approvals and clearances, and the satisfaction of other conditions to the completion of the Merger; (ii) potential litigation relating to the Merger that could be instituted by or against Catalent, Novo Holdings or their respective affiliates, directors or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the Merger will harm Catalent’s business, including current plans and operations; (iv) the ability of Catalent to retain and hire key personnel; (v) potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the Merger; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting Catalent’s business; (viii) general economic and market developments and conditions; (ix) certain restrictions during the pendency of the Merger that may impact Catalent’s ability to pursue certain business opportunities or strategic transactions; (x) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as Catalent’s response to any of the aforementioned factors; (xi) significant transaction costs associated with the Merger; (xii) the possibility that the Merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger, including in circumstances requiring Catalent to pay a termination fee or other expenses; (xiv) competitive responses to the Merger; (xv) Catalent’s management response to any of the aforementioned factors; (xvi) the risks and uncertainties pertaining to Catalent’s business, including those set forth in Catalent’s most recent Annual Report on Form 10-K and Catalent’s subsequent Quarterly Reports on Form 10-Q, as such risk factors may be amended, supplemented or superseded from time to time by other reports filed or furnished by Catalent with the Securities and Exchange Commission (“SEC”); and (xvii) the risks and uncertainties that are described in the definitive proxy statement filed with the SEC on April 15, 2024 (the “Proxy Statement”). These risks, as well as other risks associated with the Merger, are more fully discussed in the Proxy Statement. While the list of factors presented here is, and the list of factors presented in the Proxy Statement is, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, actions of governmental authorities, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on Catalent’s financial condition, results of operations, credit rating or liquidity. These forward-looking statements speak only as of the date they are made, and Catalent does not undertake to and specifically disclaims any obligation to publicly release the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

I agree